Last reviewed · How we verify
NCT03388060
(SWL) Versus (ODT) Versus Combined SWL And ODT For Radiolucent Stone
NA trial testing Ultrasound guided SWL in Urologic Diseases in 150 participants. Completed in 30 March 2018.
30 March 2018
Quick facts
| Lead sponsor | Mansoura University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 1 April 2017 |
| Primary completion | 30 March 2018 |
| Estimated completion | 30 March 2018 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Ultrasound guided SWL
- Dissolution therapy
- Combined ultrasound guided SWL and dissolution therapy
Conditions studied
- Urologic Diseases — all drugs for Urologic Diseases →
- Stone, Urinary — all drugs for Stone, Urinary →
- Stone, Kidney — all drugs for Stone, Kidney →
- ESWL — all drugs for ESWL →
Sponsor
Mansoura University
Who can join
18 and older, any sex, with Urologic Diseases or Stone, Urinary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
compare the efficacy of of ultrasound guided SWL versus dissolution therapy versus combined SWL and dissolution therapy in management of 1 - 2.5 cm renal stones.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03388060
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urologic Diseases
Currently open trials in the same condition.
- NCT07378358 — Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study · recruiting
- NCT07338292 — VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures · NA · recruiting
- NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting
- NCT06531473 — Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures · NA · recruiting
- NCT07395037 — A Study of Ward Admissions for Haematuria · recruiting
Other Mansoura University trials
Trials by the same sponsor.
- NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
- NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
- NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
- NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03388060 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mansoura University
- Last refreshed: 6 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03388060.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing